mRNA-1769
Phase 2Completed 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox, Mpox
Conditions
Smallpox, Mpox
Trial Timeline
Aug 15, 2023 → Jul 8, 2025
NCT ID
NCT05995275About mRNA-1769
mRNA-1769 is a phase 2 stage product being developed by Moderna for Smallpox, Mpox. The current trial status is completed. This product is registered under clinical trial identifier NCT05995275. Target conditions include Smallpox, Mpox.
What happened to similar drugs?
3 of 8 similar drugs in Smallpox, Mpox were approved
Approved (3) Terminated (0) Active (5)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05995275 | Phase 2 | Completed |
Competing Products
20 competing products in Smallpox, Mpox
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Smallpox vaccine, LISTER strain, from chick embryo cells | Sanofi | Phase 2 | 35 |
| MVA (smallpox vaccine) | Sanofi | Phase 1 | 21 |
| ACAM3000 MVA Vaccine | Sanofi | Phase 1 | 29 |
| MVA Smallpox vaccine + Placebo | Sanofi | Phase 2 | 35 |
| ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: Dryvax | Sanofi | Phase 2 | 27 |
| IMVAMUNE (MVA-BN) | Bavarian Nordic | Phase 2 | 32 |
| MVA-BN | Bavarian Nordic | Phase 1 | 26 |
| IMVAMUNE® | Bavarian Nordic | Phase 2 | 32 |
| LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE® | Bavarian Nordic | Phase 2 | 32 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 32 |
| FD MVA-BN | Bavarian Nordic | Phase 3 | 37 |
| IMVAMUNE® | Bavarian Nordic | Phase 3 | 37 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 32 |
| MVA-BN® (IMVAMUNE) + Placebo | Bavarian Nordic | Phase 2 | 32 |
| Elstree-BN | Bavarian Nordic | Phase 1 | 26 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 30 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 23 |
| ACAM2000® smallpox vaccine | Emergent BioSolutions | Pre-clinical | 16 |
| Brincidofovir | Emergent BioSolutions | Phase 1 | 19 |
| Vaccination with ACAM2000 | Emergent BioSolutions | Approved | 33 |